Trial readouts
What the latest Phase 2 and Phase 3 trials reported, the effect sizes that matter, and how to read the safety signals around them.
GLP-1 Records in Diabetic Neuropathy
A cross-sectional hospital study found more documented illness among neuropathy patients with GLP-1-based medication records, but no causal effect.
GLP-1 Heart Failure Meta-analysis
A 14-trial meta-analysis found a favorable signal in HFpEF, while evidence for GLP-1 receptor agonists in HFrEF remained limited.
GLP-1 rodent tumor evidence reassessed
A 2026 review argues that GLP-1 rodent thyroid tumors reflect a human-irrelevant mechanism, but long-term human risk is not settled.
Hypothalamic Obesity in Craniopharyngioma
A 2026 review found different obesity patterns after pediatric and adult craniopharyngioma, while direct age comparisons remain absent.
MASH drug cost-effectiveness model
A U.S. model found semaglutide and tirzepatide cost-effective versus standard care for MASH, with major uncertainty around prices and assumptions.
Oral semaglutide cognition cohort
A retrospective cohort linked oral semaglutide with fewer new cognitive-impairment cases than DPP-4 inhibitors, but it cannot prove prevention.
Semaglutide and a thyroid cancer case
A papillary thyroid cancer case during semaglutide use cannot establish causation, and larger human studies have not confirmed excess risk.
Semaglutide and retinal vascular events
A scoping review found more retinal vascular events reported with semaglutide than placebo, but the events were rare and estimates remain uncertain.
An oral semaglutide emulsion in rats
A lipid-based semaglutide formulation improved cell transport and glucose measures in diabetic rats, but it has not been tested in people.
Black-Market Retatrutide vs Trial Evidence
A retatrutide label does not transfer Lilly's trial results to an unknown online vial. Here is what the public evidence supports.
What 49 Online GLP-1 Prescribers Required
A secret-shopper study found rapid access to GLP-1 prescriptions across 49 US websites, often without direct clinician-patient communication.
Adolescent Obesity Drugs: 2026 Review
A 2026 review finds the strongest adolescent obesity evidence for semaglutide, while tirzepatide and CagriSema still lack comparable data.